克拉生坦治疗动脉瘤性蛛网膜下腔出血后脑血管痉挛的疗效与安全性更新:一项Meta分析
该Meta分析更新至2018年9月,纳入5项随机安慰剂对照试验,评估不同剂量克拉生坦在动脉瘤性蛛网膜下腔出血中的疗效与安全性。高剂量克拉生坦(>5 mg/h)较低剂量降低迟发性缺血性神经功能缺损、新发脑梗死和血管造影性血管痉挛的发生率,但在挽救治疗及血管痉挛相关并发症/死亡方面无显著差异。
要点
- 高剂量克拉生坦(>5 mg/h)降低迟发性缺血性神经功能缺损(OR 1.76,95%CI 1.16-2.69,P=0.008)。
- 高剂量克拉生坦降低新发脑梗死(OR 2.31,95%CI 1.34-3.95,P=0.002)。
- 高剂量克拉生坦降低血管造影性血管痉挛(OR 1.85,95%CI 1.19-2.89,P=0.007)。
核心结论
- 与低剂量克拉生坦相比,高剂量克拉生坦在预防脑血管痉挛及后续脑梗死方面显示出显著有益结局,且安全性可控。
- 高剂量克拉生坦对挽救治疗及血管痉挛相关并发症/死亡无显著影响。
研究设计与样本
- 本研究为Meta分析,检索Cochrane Library、Embase和PubMed至2018年9月,纳入5项随机安慰剂对照试验。
主要发现
- 高剂量克拉生坦(>5 mg/h)组迟发性缺血性神经功能缺损发生率较低剂量组降低(OR 1.76,95%CI 1.16-2.69,P=0.008)。
- 高剂量克拉生坦(>5 mg/h)组新发脑梗死发生率较低剂量组降低(OR 2.31,95%CI 1.34-3.95,P=0.002)。
- 高剂量克拉生坦(>5 mg/h)组血管造影性血管痉挛发生率较低剂量组降低(OR 1.85,95%CI 1.19-2.89,P=0.007)。
- 高剂量与低剂量克拉生坦在血管痉挛相关并发症/死亡、挽救治疗及不良事件方面无统计学显著差异(P>0.05)。
关键数值与推荐
- 高剂量克拉生坦(>5 mg/h)组迟发性缺血性神经功能缺损OR 1.76(95%CI 1.16-2.69,P=0.008)。
- 高剂量克拉生坦(>5 mg/h)组新发脑梗死OR 2.31(95%CI 1.34-3.95,P=0.002)。
- 高剂量克拉生坦(>5 mg/h)组血管造影性血管痉挛OR 1.85(95%CI 1.19-2.89,P=0.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The present meta-analysis was conducted to provide an update on the efficacy and safety profile of clazosentan with different doses in aneurysmal subarachnoid hemorrhage (aSAH). METHODS: We performed a comprehensive and electronic search updated to September 2018 of The Cochrane Library, Embase, and PubMed to identify relevant clinical trials. Trials of the effectiveness of clazosentan in treating cerebral vasospasm after aSAH were studied. The main outcomes included new cerebral infarction (NCI), delayed ischemic neurologic deficit (DIND), vasospasm associated with morbidity/mortality, angiographic vasospasm, rescue therapy, and adverse events. We applied RevMan 5.3 software for this meta-analysis to analyze the combined pooled odds ratios (ORs) with 95% confidence intervals (CIs) using a fixed- or random-effects model on the basis of heterogeneity. RESULTS: A total of 5 randomized placebo-controlled trials were included in this meta-analysis. Beneficial outcome was found in patients who received higher doses of clazosentan (>5 mg/h) after aSAH based on decreased incidence of DINDs (OR, 1.76; 95% CI, 1.16-2.69; P = 0.008), NCIs (OR, 2.31; 95% CI, 1.34-3.95; P = 0.002), and angiographic vasospasms (OR, 1.85; 95% CI, 1.19-2.89; P = 0.007). Meanwhile, other parameters, such as vasospasm-related morbidity/mortality, rescue therapy, and adverse events, showed no statistical significance (P > 0.05) between high and low doses of clazosentan. CONCLUSIONS: The significant beneficial outcomes of high-dose clazosentan have been proven in preventing cerebral vasospasm and subsequent cerebral infarction compared with low-dose clazosentan, with a manageable safety profile. However, high doses of clazosentan had no significant effect on rescue therapy and vasospasm-related morbidity/mortality.
引用
- Song J, Xue YQ, Wang YJ, et al. An Update on the Efficacy and Safety Profile of Clazosentan in Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis. World Neurosurg. 2018. PMID: 30496924. doi:10.1016/j.wneu.2018.11.143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。